{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:49Z","timestamp":1792788049019,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Federal Ministry of Research, Technology and Space","award":["13GW0436A"],"award-info":[{"award-number":["13GW0436A"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aim to quantify the dosimetric benefits of daily online adaptive (DOA) carbon ion stereotactic radiotherapy (CISR) in hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      13 patients received 4\u2009\u00d7\u200910.5\u00a0Gy (RBE-weighted dose) CISR to 14 HCC lesions in challenging locations (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200910: liver dome,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20093: &lt; 1\u00a0cm from intestines). All patients underwent daily in-room CT, with forward calculation of the baseline plan. Additionally, four patients were shuttled to a 1.5 Tesla MR scanner in treatment position for MRI simulation. Based on visual review of all data, the physician decided to treat or to perform offline plan adaptation and treat another day. We compare the dosimetry properties of four scenarios per fraction: (1) baseline plan, (2) no adaptation, (3) occasional offline adaptation (OOA), (4) DOA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline planning target volume (PTV) and internal target volume (ITV) coverage by the prescribed dose (median coverage: PTV: 97%, ITV: 100%) significantly decreased for no adaptation (PTV: 87.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001; ITV: 97.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) and OOA (PTV: 87.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001; ITV: 97.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), while DOA maintained high PTV coverage (PTV: 95.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.17; ITV: 100%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.53). Frequent violations of organs-at-risk (OAR) dose constraints occurred for no adaptation and OOA (both 20\/52 fractions, 38.5%). They affected the bowel, heart and esophagus up to 6\u00a0cm from the PTV. DOA led to considerably fewer (6\/52 fractions, 11.5%) and less intense violations of OAR dose constraints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daily CT- and MR-guided CISR is feasible in the liver, and demonstrates frequent violations of initial treatment planning objectives when non-adaptive or offline adaptive approaches are followed. DOA could improve target coverage and OAR protection, while particularities of carbon ions such as overdoses far from the target should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02928-4","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:15:12Z","timestamp":1790867712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daily image-guided carbon ion stereotactic radiotherapy of hepatocellular carcinoma: paving the way for MR-guided online adaptive treatment"],"prefix":"10.1186","volume":"21","author":[{"given":"Sebastian","family":"Regnery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pestana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen-Sa\u00dfmannshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Waldsperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friderike K.","family":"Longarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Seidensaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"12","key":"2928_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683\u201391.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2928_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jhep.2023.12.031","volume":"80","author":"LA Kondili","year":"2024","unstructured":"Kondili LA, Lazarus JV, Jepsen P, Murray F, Schattenberg JM, Korenjak M, et al. Inequities in primary liver cancer in Europe: The state of play. J Hepatol. 2024;80(4):645\u201360.","journal-title":"J Hepatol"},{"issue":"1","key":"2928_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"1","key":"2928_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13014-017-0851-7","volume":"12","author":"E Gkika","year":"2017","unstructured":"Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. 2017;12(1):116.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2928_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","volume":"67","author":"G Sapisochin","year":"2017","unstructured":"Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"2928_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","volume":"74","author":"TH Kim","year":"2021","unstructured":"Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. J Hepatol. 2021;74(3):603\u201312.","journal-title":"J Hepatol"},{"issue":"11","key":"2928_CR7","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.3390\/curroncol29110692","volume":"29","author":"T Comito","year":"2022","unstructured":"Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, et al. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). Curr Oncol. 2022;29(11):8802\u201313.","journal-title":"Curr Oncol"},{"issue":"22","key":"2928_CR8","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/cncr.34965","volume":"129","author":"DA Bush","year":"2023","unstructured":"Bush DA, Volk M, Smith JC, Reeves ME, Sanghvi S, Slater JD, et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial. Cancer. 2023;129(22):3554\u201363.","journal-title":"Cancer"},{"issue":"1","key":"2928_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","volume":"117","author":"A M\u00e9ndez Romero","year":"2023","unstructured":"M\u00e9ndez Romero A, van der Holt B, Willemssen F, de Man RA, Heijmen BJM, Habraken S, et al. Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys. 2023;117(1):45\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2928_CR10","doi-asserted-by":"publisher","first-page":"101063","DOI":"10.1016\/j.jhepr.2024.101063","volume":"6","author":"P Hoegen-Sa\u00dfmannshausen","year":"2024","unstructured":"Hoegen-Sa\u00dfmannshausen P, Naumann P, Hoffmeister-Wittmann P, Ben Harrabi S, Seidensaal K, Weykamp F, et al. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial. JHEP Rep. 2024;6(6):101063.","journal-title":"JHEP Rep"},{"key":"2928_CR11","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2147\/JHC.S292516","volume":"8","author":"B Abousaida","year":"2021","unstructured":"Abousaida B, Seneviratne D, Hoppe BS, Ko SJ, Asaithamby A, Cucinotta FA, et al. Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1169\u201379.","journal-title":"J Hepatocell Carcinoma"},{"issue":"20","key":"2928_CR12","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1002\/cncr.30816","volume":"123","author":"G Kasuya","year":"2017","unstructured":"Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer. 2017;123(20):3955\u201365.","journal-title":"Cancer"},{"issue":"3","key":"2928_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1053\/j.seminoncol.2019.07.005","volume":"46","author":"T Rackwitz","year":"2019","unstructured":"Rackwitz T, Debus J. Clinical applications of proton and carbon ion therapy. Semin Oncol. 2019;46(3):226\u201332.","journal-title":"Semin Oncol"},{"key":"2928_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2022.09.005","volume":"176","author":"S Molinelli","year":"2022","unstructured":"Molinelli S, Vai A, Russo S, Loap P, Meschini G, Paganelli C, et al. The role of multiple anatomical scenarios in plan optimization for carbon ion radiotherapy of pancreatic cancer. Radiother Oncol. 2022;176:1\u20138.","journal-title":"Radiother Oncol"},{"key":"2928_CR15","unstructured":"Longarino FK, Maguire U, Beyer C, Pestana R, Regnery S, Debus J et al. Stability of liver position in a shuttle-based workflow for daily online magnetic resonance imaging-guided particle therapy. Phys Imaging Radiat Oncol."},{"key":"2928_CR16","doi-asserted-by":"crossref","unstructured":"Bobi\u0107 M, Choulilitsa E, Lee H, Czerska K, Christensen JB, Mayor A et al. Multi-institutional experimental validation of online adaptive proton therapy workflows. Phys Med Biol. 2024;69(16).","DOI":"10.1088\/1361-6560\/ad6527"},{"key":"2928_CR17","doi-asserted-by":"crossref","unstructured":"Choulilitsa E, Bobi\u0107 M, Winey B, Paganetti H, Lomax AJ, Albertini F. Multi-institution investigations of online daily adaptive proton strategies for head and neck cancer patients. Phys Med Biol. 2025;70(6).","DOI":"10.1088\/1361-6560\/adbb51"},{"key":"2928_CR18","doi-asserted-by":"crossref","unstructured":"Albertini F, Czerska K, Vazquez M, Andaca I, Bachtiary B, Besson R et al. First clinical implementation of a highly efficient daily online adapted proton therapy (DAPT) workflow. Phys Med Biol. 2024;69(21).","DOI":"10.1088\/1361-6560\/ad7cbd"},{"issue":"2","key":"2928_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.radonc.2018.08.009","volume":"129","author":"M Tyran","year":"2018","unstructured":"Tyran M, Jiang N, Cao M, Raldow A, Lamb JM, Low D, et al. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Radiother Oncol. 2018;129(2):319\u201325.","journal-title":"Radiother Oncol"},{"key":"2928_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejmp.2020.07.027","volume":"77","author":"KR Padgett","year":"2020","unstructured":"Padgett KR, Simpson G, Asher D, Portelance L, Bossart E, Dogan N. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Phys Med. 2020;77:54\u201363.","journal-title":"Phys Med"},{"issue":"24","key":"2928_CR21","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.3390\/cancers14246041","volume":"14","author":"F Weykamp","year":"2022","unstructured":"Weykamp F, Katsigiannopulos E, Piskorski L, Regnery S, Hoegen P, Ristau J, et al. Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases. Cancers. 2022;14(24):6041.","journal-title":"Cancers"},{"key":"2928_CR22","doi-asserted-by":"publisher","first-page":"100567","DOI":"10.1016\/j.ctro.2022.100567","volume":"39","author":"P Hoegen","year":"2023","unstructured":"Hoegen P, Katsigiannopulos E, Buchele C, Regnery S, Weykamp F, Sandrini E, et al. Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk. Clin Translational Radiation Oncol. 2023;39:100567.","journal-title":"Clin Translational Radiation Oncol"},{"issue":"3 Suppl","key":"2928_CR23","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2928_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman R. A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022;112(1):4\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2928_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1118\/1.4894702","volume":"42","author":"O Weistrand","year":"2015","unstructured":"Weistrand O, Svensson S. The ANACONDA algorithm for deformable image registration in radiotherapy. Med Phys. 2015;42(1):40\u201353.","journal-title":"Med Phys"},{"issue":"1","key":"2928_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","volume":"80","author":"PC B\u00fcrkner","year":"2017","unstructured":"B\u00fcrkner PC. brms: An R package for Bayesian multilevel models using Stan. J Stat Softw. 2017;80(1):1\u201328.","journal-title":"J Stat Softw"},{"key":"2928_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1088\/1361-6560\/ac1ef2","volume":"66","author":"M Moteabbed","year":"2021","unstructured":"Moteabbed M, Smeets J, Hong TS, Janssens G, Labarbe R, Wolfgang JA, et al. Toward MR-integrated proton therapy: modeling the potential benefits for liver tumors. Phys Med Biol. 2021;66:19.","journal-title":"Phys Med Biol"},{"key":"2928_CR28","first-page":"100598","volume":"39","author":"M Huiskes","year":"2023","unstructured":"Huiskes M, Astreinidou E, Kong W, Breedveld S, Heijmen B, Rasch C. Dosimetric impact of adaptive proton therapy in head and neck cancer - A review. Clin Transl Radiat Oncol. 2023;39:100598.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2928_CR29","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.phro.2023.100459","volume":"27","author":"VT Taasti","year":"2023","unstructured":"Taasti VT, Hattu D, Peeters S, van der Salm A, van Loon J, de Ruysscher D, et al. Clinical evaluation of synthetic computed tomography methods in adaptive proton therapy of lung cancer patients. Phys Imaging Radiat Oncol. 2023;27:100459.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"2928_CR30","doi-asserted-by":"publisher","first-page":"110548","DOI":"10.1016\/j.radonc.2024.110548","volume":"201","author":"M Oud","year":"2024","unstructured":"Oud M, Breedveld S, Gi\u017cy\u0144ska M, Chen YH, Habraken S, Perk\u00f3 Z, et al. Dosimetric advantages of adaptive IMPT vs. Enhanced workload and treatment time - A need for automation. Radiother Oncol. 2024;201:110548.","journal-title":"Radiother Oncol"},{"key":"2928_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.11.001","volume":"177","author":"S Visser","year":"2022","unstructured":"Visser S, C OR, Dieters M, Mul VE, Niezink AGH, van der Schaaf A, et al. Robustness assessment of clinical adaptive proton and photon radiotherapy for oesophageal cancer in the model-based approach. Radiother Oncol. 2022;177:197\u2013204.","journal-title":"Radiother Oncol"},{"issue":"6","key":"2928_CR32","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1002\/mp.15563","volume":"49","author":"S Jia","year":"2022","unstructured":"Jia S, Chen J, Ma N, Zhao J, Mao J, Jiang G, et al. Adaptive carbon ion radiotherapy for locally advanced non-small cell lung cancer: Organ-sparing potential and target coverage. Med Phys. 2022;49(6):3980\u20139.","journal-title":"Med Phys"},{"key":"2928_CR33","doi-asserted-by":"crossref","unstructured":"Nenoff L, Sudhyadhom A, Lau J, Sharp GC, Paganetti H, Pursley J. Comparing Predicted Toxicities between Hypofractionated Proton and Photon Radiotherapy of Liver Cancer Patients with Different Adaptive Schemes. Cancers (Basel). 2023;15(18).","DOI":"10.3390\/cancers15184592"},{"issue":"3","key":"2928_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","volume":"125","author":"O Bohoudi","year":"2017","unstructured":"Bohoudi O, Bruynzeel AME, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ, et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Radiother Oncol. 2017;125(3):439\u201344.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2928_CR35","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.prro.2020.07.003","volume":"11","author":"G G\u00fcng\u00f6r","year":"2021","unstructured":"G\u00fcng\u00f6r G, Serbez \u0130, Temur B, G\u00fcr G, Kayal\u0131lar N, Mustafayev TZ, et al. Time Analysis of Online Adaptive Magnetic Resonance-Guided Radiation Therapy Workflow According to Anatomical Sites. Pract Radiat Oncol. 2021;11(1):e11\u201321.","journal-title":"Pract Radiat Oncol"},{"key":"2928_CR36","doi-asserted-by":"publisher","first-page":"100239","DOI":"10.1016\/j.tipsro.2024.100239","volume":"29","author":"C Votta","year":"2024","unstructured":"Votta C, Iacovone S, Turco G, Carrozzo V, Vagni M, Scalia A, et al. Evaluation of clinical parallel workflow in online adaptive MR-guided Radiotherapy: A detailed assessment of treatment session times. Tech Innov Patient Support Radiat Oncol. 2024;29:100239.","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"4","key":"2928_CR37","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/mp.17580","volume":"52","author":"M Kawula","year":"2025","unstructured":"Kawula M, Marschner S, Wei C, Ribeiro MF, Corradini S, Belka C, et al. Personalized deep learning auto-segmentation models for adaptive fractionated magnetic resonance-guided radiation therapy of the abdomen. Med Phys. 2025;52(4):2295\u2013304.","journal-title":"Med Phys"},{"key":"2928_CR38","doi-asserted-by":"crossref","unstructured":"Julius Bl\u00f6cker T, Delopoulos N, Palacios MA, Kl\u00fcter S, H\u00f6rner-Rieber J, Rippke C et al. GTV segmentation in MRI guided radiotherapy with promptable foundation models. Phys Med Biol. 2025;71(1).","DOI":"10.1088\/1361-6560\/ae2db9"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02928-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:02:11Z","timestamp":1790982131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02928-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02928-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All analyses were conducted in compliance with the Declaration of Helsinki. The institutional review board of the University Hospital Heidelberg approved the study (S-586\/2024).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not apply.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.R. received a grant from Accuray Inc. PHS received compensation for advisory boards from Novocure GmbH. F.W. received speaker fees from AstraZeneca, Varian Medical Systems, Siemens Healthineers, Chulabhorn Royal Academy and Merck Sharp & Dohme and travel support for attending meetings from AstraZeneca, Varian Medical Systems, Novocure GmbH, German Center for Lung Research (DZL), Fraunhofer MEVIS, Chulabhorn Royal Academy and Micropos Medical as well as compensation for advisory boards from Novocure GmbH and Merck Sharp & Dohme. J. L. received travel reimbursements from RaySearch Laboratories AB, Micropos Medical and Varian Medical Systems as well as speaker fees from Accuray Inc. and AstraZeneca. S. K. received speaker fees from Siemens Healthineers and a grant as well as speaker fees und travel reimbursement from Accuray Inc. J.D. reports grants from Vision RT Limited, RaySearch Laboratories AB, Siemens Healthcare GmbH, Merck Serono GmbH, PTW-Freiburg Dr. Pychlau GmbH and Accuray Inc. JD reports receipt of an experimental accelerator by IntraOP.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"133"}}